A share price of Pacira BioSciences Inc [PCRX] is currently trading at $26.33, up 0.34%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The PCRX shares have gain 7.38% over the last week, with a monthly amount glided 39.02%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Pacira BioSciences Inc [NASDAQ: PCRX] stock has seen the most recent analyst activity on January 30, 2025, when Truist upgraded its rating to a Hold and also boosted its price target to $25 from $8. Previously, Truist downgraded its rating to Sell on August 13, 2024, and dropped its price target to $8. On August 12, 2024, downgrade downgraded it’s rating to Sector Perform and revised its price target to $14 on the stock. Raymond James downgraded its rating to a Mkt Perform. Piper Sandler downgraded its rating to a Neutral and reduced its price target to $11 on August 12, 2024. JP Morgan downgraded its rating to Underweight for this stock on August 12, 2024, and downed its price target to $10. In a note dated July 03, 2024, Barclays downgraded an Equal Weight rating on this stock and revised its target price from $38 to $25.
Pacira BioSciences Inc experienced fluctuations in its stock price throughout the past year between $11.16 and $34.01. Currently, Wall Street analysts expect the stock to reach $18.33 within the next 12 months. Pacira BioSciences Inc [NASDAQ: PCRX] shares were valued at $26.33 at the most recent close of the market. An investor can expect a potential drop of -30.38% based on the average PCRX price forecast.
Analyzing the PCRX fundamentals
Trailing Twelve Months sales for Pacira BioSciences Inc [NASDAQ:PCRX] were 694.96M which represents 2.83% growth. Gross Profit Margin for this corporation currently stands at 0.68% with Operating Profit Margin at -0.09%, Pretax Profit Margin comes in at -0.08%, and Net Profit Margin reading is -0.13%. To continue investigating profitability, this company’s Return on Assets is posted at -0.06, Equity is -0.11 and Total Capital is -0.05. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.86.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 25.88 points at the first support level, and at 25.43 for the second support level. However, for the 1st resistance point, the stock is sitting at 26.64, and for the 2nd resistance point, it is at 26.95.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Pacira BioSciences Inc [NASDAQ:PCRX] is 2.25. As well, the Quick Ratio is 1.89, while the Cash Ratio is 0.8. Considering the valuation of this stock, the price to sales ratio is 1.75, the price to book ratio is 1.62.
Transactions by insiders
Recent insider trading involved SLONIN JONATHAN, Chief Medical Officer, that happened on Jan 06 ’25 when 879.0 shares were sold. Officer, SLONIN JONATHAN completed a deal on Jan 06 ’25 to buy 879.0 shares. Meanwhile, Chief Operating Officer GAUGLER DARYL sold 500.0 shares on Dec 13 ’24.
